Drugs / Pomalidomide
Pomalidomide
also known as
CC-4047 · POM · Pomalyst · Imnovid · Actimid · IMID 3 · Imnovid (previously pomalidomide celgene) · Pomalidomida · +7 more
Other / unclassified targets TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | POMALYST | — | 2015-04-23 – 2020-11-20 | fda.gov ↗ |
| Approved | EU (EMA) | Imnovid (previously Pomalidomide Celgene) | — | 2013-08-05 | europa.eu ↗ |
| Approved | US (FDA) | POMALYST | — | 2013-02-08 | fda.gov ↗ |
Trials 202 · started per year
today
US approved 2013
EU approved 2013
1
5
4
3
6
9
16
10
18
10
9
11
6
9
8
19
22
10
8
8
7
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 148 trials | ||||||
| Phase 1 | NCT07532525 | Sep 2026 → Oct 2027 expected | B-cell acute lymphoblastic leukemia, precursor B-cell acute lymphoblastic leukemia | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05389423 | Jun 2023 → Jun 2028 expected | Burkitt lymphoma, plasmablastic lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT05651932 | Feb 2023 → Dec 2027 expected | plasma cell myeloma | K36 Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05556616 | Jan 2023 → Jun 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05556798 | Oct 2022 → Oct 2026 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05137054 | Aug 2022 → Mar 2028 expected | plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT04895410 | Jan → Jun 2022 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT04902443 | Dec 2021 → Dec 2026 expected | Kaposi's sarcoma, lymphoid neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT04667663 | Dec 2021 → Apr 2022 overdue | plasma cell myeloma | Cancer Trials Ireland | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05050097 | Sep 2021 → Mar 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04392648 | Jun 2020 → Nov 2023 | refractory plasma cell neoplasm | Teva Branded Pharmaceutical Products R&D, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04108195 | Feb 2020 → Apr 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03828292 | Mar 2019 → Apr 2023 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03798314 | Jan 2019 → Dec 2020 | central nervous system non-hodgkin lymphoma, primary vitreoretinal large b-cell lymphoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03582033 | Nov 2018 → Nov 2023 | plasma cell myeloma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03269136 | Nov 2017 → Jan 2024 | plasma cell myeloma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03287908 | Nov 2017 → Jun 2023 | refractory plasma cell neoplasm | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT03015922 | Jun 2017 → Sep 2021 | plasma cell myeloma | University of Leeds | Unknown | No outcome recorded |
| Phase 1 | NCT03023527 | Jan 2017 → Jan 2018 | plasma cell myeloma | PETHEMA Foundation | Terminated | No outcome recorded |
| Phase 1 | NCT02900716 | Sep 2016 → Nov 2020 | B-cell chronic lymphocytic leukemia | Zhejiang DTRM Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT02659930 | Jan 2016 → Jan 2028 expected | Kaposi's sarcoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02616640 | Jan 2016 → Nov 2018 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02431208 | Jul 2015 → Mar 2021 | plasma cell myeloma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02415153 | Jul 2015 → Jul 2019 | childhood brain stem glioma, neurofibromatosis type 1, optic pathway glioma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02283775 | May 2015 → May 2021 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02287558 | Jan 2015 → Jun 2019 | hereditary hemorrhagic telangiectasia | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02189343 | Sep 2014 → Apr 2018 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01999335 | Jul 2014 → Apr 2019 | plasma cell myeloma | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT01889420 | Jul 2014 → Jun 2015 | plasma cell myeloma | New Mexico Cancer Research Alliance | Terminated | No outcome recorded |
| Phase 1 | NCT02103335 | Jun 2014 → Oct 2016 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02168205 | May → Sep 2014 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02071888 | Feb 2014 → Apr 2016 | T-cell non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, plasma cell myeloma | Calithera Biosciences, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01807286 | Jan 2014 → Feb 2016 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02029950 | Dec 2013 → May 2020 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01986894 | Oct → Dec 2013 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01722305 | Apr 2013 → Jun 2016 | diffuse large B-cell lymphoma of the central nervous system, intraocular lymphoma, retina lymphoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01835561 | Mar 2013 → Aug 2014 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01728259 | Mar 2013 → Oct 2018 | light chain deposition disease, primary systemic amyloidosis | Barbara Ann Karmanos Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT01707407 | Sep → Nov 2012 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01575925 | Jun 2012 → Aug 2018 | impaired renal function disease, plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01562405 | May 2012 → Dec 2026 expected | plasma cell myeloma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01568294 | Apr 2012 → Jul 2015 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01497093 | Feb 2012 → Jul 2019 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01474330 | Aug → Oct 2011 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01198067 | Oct 2010 → May 2025 | Waldenstrom macroglobulinemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01078974 | May 2010 → Sep 2015 | Waldenstrom macroglobulinemia | Steven P. Treon, MD, PhD | Terminated | No outcome recorded |
| Phase 1 | NCT01522547 | Aug 2007 → Oct 2012 | sickle cell disease | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00482521 | Mar 2007 → Sep 2010 | cancer of unknown primary site | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/232 trials | ||||||
| Phase 1/2 | NCT07463807 | Jul → Aug 2026 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07441954 | Mar 2026 → Dec 2027 expected | indolent B-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06855823 | Jan 2025 → Dec 2026 expected | peripheral T-cell lymphoma, not otherwise specified | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06554561 | Aug 2024 → Aug 2026 overdue | primary central nervous system lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06246162 | Nov 2023 → Nov 2025 overdue | plasma cell myeloma | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05408026 | Oct 2022 → Oct 2025 | refractory plasma cell neoplasm | Alliance Foundation Trials, LLC. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04973605 | Sep 2021 → Nov 2026 expected | refractory plasma cell neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04762745 | Feb 2021 → Feb 2022 | plasma cell myeloma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04126200 | Oct 2019 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02343042 | Oct 2015 → Apr 2027 expected | plasma cell myeloma | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02542657 | Oct 2015 → Aug 2025 overdue | plasma cell myeloma | Joseph Tuscano | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02384083 | Sep 2015 → Feb 2018 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT02289222 | Dec 2014 → Aug 2017 | plasma cell myeloma | Ashraf Badros | Terminated | No outcome recorded |
| Phase 1/2 | NCT01946152 | Mar 2014 → Mar 2020 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02004275 | Feb 2014 → Dec 2021 | plasma cell myeloma | Alliance for Clinical Trials in Oncology | Unknown | No outcome recorded |
| Phase 1/2 | NCT01979276 | Nov 2013 → Oct 2016 | plasma cell myeloma | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01644110 | Aug 2013 → Apr 2024 | myelofibrosis, myelofibrosis with myeloid metaplasia | University of Ulm | Completed | No outcome recorded |
| Phase 1/2 | NCT01754402 | Jan 2013 → Dec 2016 | plasma cell myeloma | Cristina Gasparetto | Unknown | No outcome recorded |
| Phase 1/2 | NCT01592370 | Aug 2012 → Sep 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01570387 | Jun 2012 → Nov 2018 | AL amyloidosis | Boston Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01541332 | Feb 2012 → Dec 2016 | plasma cell myeloma | Oncotherapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT01522872 | Feb 2012 → Sep 2016 | plasma cell myeloma | Threshold Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT01495598 | Jan 2012 → May 2022 | Kaposi's sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01464034 | Nov 2011 → Jul 2020 | plasma cell myeloma | Criterium, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01432600 | Nov 2011 → Aug 2016 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01212952 | Sep 2011 → Aug 2017 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01421186 | Jul 2011 → Aug 2020 | plasma cell myeloma | MorphoSys AG | Completed | No outcome recorded |
| Phase 1/2 | NCT01166113 | Jul 2010 → Jun 2011 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | No outcome recorded |
| Phase 1/2 | NCT00833833 | Jun 2008 → Apr 2011 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT00669578 | May 2008 → Jul 2010 | myelofibrosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00537511 | Feb 2008 → Nov 2010 | small cell carcinoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00540579 | Nov 2007 → Dec 2008 | malignant pancreatic neoplasm | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 288 trials | ||||||
| Phase 2 | NCT07560449 | Jun 2026 → Jun 2028 expected | plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227311 | Apr 2026 → Aug 2030 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT07523737 | Apr 2026 → Mar 2028 expected | diffuse large B-cell lymphoma, primary central nervous system lymphoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07018050 | Sep 2025 → Nov 2027 expected | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07312188 | Jul 2025 → May 2028 expected | refractory plasma cell neoplasm | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 2 | NCT05922501 | May 2024 → Dec 2028 expected | plasma cell myeloma | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06342466 | May 2024 → Dec 2026 expected | AL amyloidosis | Jin Lu, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT05911321 | Dec 2023 → Jun 2025 overdue | plasma cell myeloma, refractory plasma cell neoplasm | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06158412 | Nov 2023 → Dec 2025 overdue | plasma cell myeloma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05789303 | May 2023 → Jul 2028 expected | plasma cell myeloma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT05432414 | Dec 2022 → Dec 2023 | plasma cell myeloma | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05931328 | Oct 2022 → Oct 2024 overdue | primary central nervous system lymphoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT05478993 | Oct 2022 → Jul 2024 | plasma cell myeloma | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04802161 | Aug 2022 → Nov 2024 overdue | acute myeloid leukemia with multilineage dysplasia, chronic myelomonocytic leukemia, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05208307 | Jul 2022 → Oct 2026 expected | plasma cell myeloma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT06255847 | Jun 2022 → Jun 2025 | plasma cell myeloma | Shanxi Bethune Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05288062 | Jun 2022 → Feb 2024 | smoldering plasma cell myeloma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT04850599 | Jun 2022 → Oct 2027 expected | plasma cell myeloma | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05348213 | May 2022 → Jun 2025 overdue | diffuse large B-cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05390749 | Apr 2022 → Apr 2024 | primary central nervous system lymphoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04577755 | Mar 2022 → Oct 2026 expected | Kaposi's sarcoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04941937 | Jan 2022 → Dec 2025 | plasma cell myeloma | Juan Du | Unknown | No outcome recorded |
| Phase 2 | NCT04835129 | Jan 2022 → Apr 2027 expected | plasma cell myeloma | Medical College of Wisconsin | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04843579 | Dec 2021 → Nov 2022 | plasma cell myeloma | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 2 | NCT04925193 | Nov 2021 → Aug 2024 overdue | plasma cell myeloma | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04892446 | Nov 2021 → Apr 2024 | plasma cell myeloma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT04302324 | Oct 2021 → May 2024 overdue | plasma cell myeloma, refractory plasma cell neoplasm | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05509374 | Oct 2021 → Jun 2024 | plasma cell myeloma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04883242 | Jul 2021 → Dec 2026 expected | plasma cell myeloma | University of Washington | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04895917 | Jun 2021 → Dec 2024 | AL amyloidosis | Fondazione IRCCS Policlinico San Matteo di Pavia | Terminated | No outcome recorded |
| Phase 2 | NCT03601806 | Apr 2021 → Nov 2024 | HIV infectious disease, Kaposi's sarcoma | AIDS Malignancy Consortium | Completed | No outcome recorded |
| Phase 2 | NCT04270175 | Apr 2021 → Jan 2027 expected | AL amyloidosis | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04584307 | Apr 2021 → Dec 2023 | plasma cell myeloma | Natalie Callendar | Withdrawn | No outcome recorded |
| Phase 2 | NCT04661137 | Mar 2021 → Feb 2027 | plasma cell myeloma | Hackensack Meridian Health | Suspended | No outcome recorded |
| Phase 2 | NCT04508790 | Nov 2020 → Feb 2027 expected | plasma cell myeloma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04287855 | Aug 2020 → Apr 2025 | plasma cell myeloma | Poitiers University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04191616 | Aug 2020 → Nov 2022 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT03959358 | Jul 2020 → Jun 2022 | amyloidosis, plasma cell myeloma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT04305444 | Apr 2020 → Dec 2024 | B-cell chronic lymphocytic leukemia, Richter transformation, diffuse large B-cell lymphoma, follicular lymphoma | Zhejiang DTRM Biopharma | Terminated | No outcome recorded |
| Phase 2 | NCT03683277 | Nov 2019 → Dec 2022 | disease of genetic or genomic mechanism, plasma cell myeloma, refractory plasma cell neoplasm | Intergroupe Francophone du Myelome | Terminated | No outcome recorded |
| Phase 2 | NCT03910244 | Oct 2019 → Sep 2023 | hereditary hemorrhagic telangiectasia | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT04124497 | Jul 2019 → Jul 2027 expected | chromosome 17p deletion, plasma cell myeloma | Fondazione EMN Italy Onlus | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03756896 | Jan 2019 → Jun 2025 overdue | plasma cell myeloma | Emory University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03713294 | Jan 2019 → Feb 2024 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03227432 | Dec 2018 → Dec 2021 | plasma cell myeloma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT03590652 | Oct 2018 → Jul 2025 | refractory plasma cell neoplasm | University of California, San Diego | Terminated | No outcome recorded |
| Phase 2 | NCT03520985 | Oct 2018 → Feb 2021 | refractory plasma cell neoplasm | Swiss Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03731832 | Sep 2018 → Apr 2024 | plasma cell myeloma | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03601624 | Sep → Dec 2018 | plasma cell myeloma | Institute for Social Security and Services for State Workers | Unknown | No outcome recorded |
| Phase 2 | NCT03030261 | Nov 2017 → Sep 2022 overdue | plasma cell myeloma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03215524 | Oct 2017 → Jun 2022 | plasma cell myeloma | Canadian Myeloma Research Group | Completed | No outcome recorded |
| Phase 2 | NCT03257631 | Sep 2017 → Sep 2023 | medulloblastoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03202628 | Jul 2017 → Apr 2021 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03113942 | Jun 2017 → Mar 2019 | squamous cell intraepithelial neoplasia | Kirby Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03104270 | Mar 2017 → Oct 2019 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT04243109 | Feb 2017 → May 2019 | plasma cell myeloma | Maimónides Biomedical Research Institute of Córdoba | Terminated | No outcome recorded |
| Phase 2 | NCT02807454 | Jul 2016 → Jan 2022 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT02718833 | Jun 2016 → Dec 2026 expected | plasma cell myeloma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02406222 | Mar 2016 → Dec 2022 overdue | plasma cell myeloma | University of Leeds | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02612779 | Feb 2016 → Jul 2019 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02547662 | Dec 2015 → Oct 2020 | plasma cell leukemia, plasma cell myeloma, plasmacytoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02578121 | Dec 2015 → Jan 2017 | plasma cell myeloma | University of Arkansas | Withdrawn | No outcome recorded |
| Phase 2 | NCT03242460 | May 2015 → Apr 2019 | refractory plasma cell neoplasm | Kosin University Gospel Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02158702 | Nov 2014 → Feb 2018 | plasma cell myeloma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT02188368 | Jul 2014 → Oct 2020 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT02176213 | Jun 2014 → May 2019 | plasma cell myeloma | Ajai Chari | Completed | No outcome recorded |
| Phase 2 | NCT01946477 | May 2014 → Apr 2025 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02244125 | Apr 2014 → Jan 2017 | plasma cell myeloma | Institut Curie | Completed | No outcome recorded |
| Phase 2 | NCT02046915 | Apr 2014 → Aug 2016 | refractory plasma cell neoplasm | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2 | NCT01794039 | Mar 2014 → Nov 2016 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02045017 | Feb 2014 → Jan 2017 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02011113 | Dec 2013 → Sep 2014 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01745588 | Dec 2012 → Sep 2025 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01688466 | Aug 2012 → Mar 2017 | chronic graft versus host disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01559129 | Aug 2012 → Nov 2016 | interstitial lung disease, systemic sclerosis | Celgene Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT01510613 | Feb 2012 → Dec 2016 | AL amyloidosis | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
| Phase 2 | NCT01745640 | Jan 2012 → Dec 2015 | plasma cell myeloma | University Hospital, Lille | Completed | No outcome recorded |
| Phase 2 | NCT01177735 | Oct 2011 → Sep 2013 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 2 | NCT01319422 | Jun 2011 → Nov 2014 | plasma cell myeloma | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT01159574 | Aug 2010 → May 2015 | plasma cell myeloma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT01135199 | Apr → Jun 2010 | pulmonary fibrosis | Stanford University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00949364 | Dec 2009 → Dec 2016 | myeloproliferative neoplasm | University of Ulm | Completed | No outcome recorded |
| Phase 2 | NCT00946270 | Jul 2009 → May 2018 | acquired polycythemia vera, thrombocytosis disease | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00770757 | Feb 2009 → Oct 2010 | graft versus host disease | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00717522 | Aug 2008 → Jan 2009 | soft tissue sarcoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00558896 | Nov 2007 → Sep 2012 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00463385 | Apr 2007 → May 2009 | myelofibrosis, myelofibrosis with myeloid metaplasia | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00072722 | Sep 2003 → Apr 2005 | prostate cancer | Celgene Corporation | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06879379 | Mar 2025 → Mar 2028 expected | plasma cell myeloma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 318 trials | ||||||
| Phase 3 | NCT07222761 | Jan 2026 → May 2029 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07138209 | Nov 2025 → Dec 2027 expected | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06158841 | May 2024 → Dec 2027 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT06208150 | Jan 2024 → Apr 2026 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05572515 | Mar 2023 → Oct 2025 overdue | refractory plasma cell neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05455320 | Oct 2022 → Jul 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05519085 | Sep 2022 → Jan 2027 expected | refractory plasma cell neoplasm | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT05083169 | Oct 2021 → Dec 2028 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05236621 | Jan 2021 → Jun 2022 | plasma cell myeloma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04181827 | Jun 2020 → May 2024 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03651128 | Apr 2019 → Apr 2026 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02916420 | Sep 2016 → Jun 2018 | plasma cell myeloma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03440411 | Feb 2016 → Dec 2019 | plasma cell myeloma | Fondazione EMN Italy Onlus | Terminated | No outcome recorded |
| Phase 3 | NCT01734928 | Jan 2013 → May 2022 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01712789 | Nov 2012 → Dec 2019 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01311687 | Mar 2011 → Mar 2013 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01324947 | Mar 2011 → Jul 2014 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01178281 | Sep 2010 → Jan 2013 | myelofibrosis, primary myelofibrosis | Celgene Corporation | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05555329 | Dec 2022 → Feb 2024 | plasma cell myeloma | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT05183139 | Jun 2022 → Dec 2026 | plasma cell myeloma | Takeda | Withdrawn | No outcome recorded |
| Phase 4 | NCT04989140 | Jul 2021 → Jul 2024 | plasma cell myeloma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07257510 | Aug 2025 → Aug 2028 expected | mantle cell lymphoma | Peking University Third Hospital | Recruiting | No outcome recorded |
| — | NCT07015021 | Jun 2025 → Sep 2026 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| — | NCT06924424 | Mar 2025 → Dec 2026 expected | plasma cell myeloma | Peking University People's Hospital | Active not recruiting | No outcome recorded |
| — | NCT07072208 | Nov 2024 → May 2027 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT06832228 | Sep 2024 → Sep 2025 overdue | diffuse large B-cell lymphoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| — | NCT06455748 | Mar 2024 → Jan 2025 | AL amyloidosis | Yongyong MA | Unknown | No outcome recorded |
| — | NCT05809180 | Jan 2023 → Jul 2025 | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| — | NCT06376214 | Jan 2023 → Dec 2025 overdue | AL amyloidosis | Nanjing University School of Medicine | Recruiting | No outcome recorded |
| — | NCT05378971 | May 2022 → May 2025 | plasma cell myeloma | LanZhou University | Unknown | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT03763370 | — | plasma cell myeloma | GlaxoSmithKline | Available | No outcome recorded |
| — | NCT01632826 | — | plasma cell myeloma | Celgene Corporation | Approved for marketing | No outcome recorded |
| — | NCT03723096 | — | plasma cell myeloma | Celgene Corporation | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 87 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01537861 Background | Jun 2012 → Feb 2014 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT06768489 Background | Dec 2024 → Jan 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05828459 Background | Jul 2023 → Jan 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | Onward Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05259839 Background | Oct 2022 → Sep 2033 expected | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04910568 Background | Jul 2021 → Dec 2028 expected | plasma cell myeloma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04355039 Background | Jul 2021 → Jul 2023 | refractory plasma cell neoplasm | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT04722146 Background | Mar 2021 → Oct 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04045795 Background | Aug 2019 → Mar 2024 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03984097 Background | Jul 2019 → Mar 2026 | plasma cell myeloma | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03657420 Background | May 2019 → Sep 2021 | plasma cell myeloma | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 1 | NCT03143985 Background | Jul 2017 → Feb 2022 | plasma cell myeloma | Koen van Besien | Completed | No outcome recorded |
| Phase 1 | NCT02939183 Background | Jan 2017 → Oct 2022 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02569320 Background | May 2016 → Nov 2020 | plasma cell myeloma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02400242 Background | May 2015 → Jun 2024 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT02462525 Background | May 2015 → Dec 2017 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT01998971 Background | Feb 2014 → Jan 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/225 trials | ||||||
| Phase 1/2 | NCT06953960 Comparator | Jul 2025 → Dec 2030 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06660498 Comparator | May 2025 → Mar 2027 expected | HIV infectious disease | University of Aarhus | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06106945 Background | Dec 2023 → Aug 2027 expected | plasma cell myeloma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05714839 Background | Jun 2023 → Aug 2028 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05451771 Comparator | Oct 2022 → Sep 2027 expected | AL amyloidosis | Columbia University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05581875 Background | Oct 2022 → Oct 2026 expected | corneal disorder, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07150104 Background | Aug 2022 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04942067 Background | Dec 2021 → Sep 2024 | amyloidosis, plasma cell myeloma | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05205252 Comparator | Dec 2021 → Jul 2023 | refractory hematologic cancer | Epizyme, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04764942 Background | May 2021 → May 2026 overdue | plasma cell myeloma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04643002 Comparator | Jan 2021 → Sep 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04150965 Background | Jul 2020 → Aug 2024 | plasma cell myeloma, refractory plasma cell neoplasm | Multiple Myeloma Research Consortium | Terminated | No outcome recorded |
| Phase 1/2 | NCT04094961 Background | Sep 2019 → Jun 2025 overdue | plasma cell myeloma | Omar Nadeem, MD | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04068597 Background | Aug 2019 → Mar 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03732703 Background | Apr 2019 → Dec 2024 | refractory plasma cell neoplasm | Multiple Myeloma Research Consortium | Completed | No outcome recorded |
| Phase 1/2 | NCT03715478 Background | Nov 2018 → Jun 2025 overdue | refractory plasma cell neoplasm | Canadian Myeloma Research Group | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03439280 Background | Apr 2018 → Jan 2022 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02548962 Background | Mar 2016 → Jun 2018 | plasma cell myeloma | Pharmacyclics LLC. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02265510 Background | Sep 2014 → Feb 2019 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02206425 Background | Sep 2014 → Jan 2018 | plasma cell myeloma | Oncotherapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT02228512 Comparator | Aug 2014 → May 2015 | large B-cell lymphoma, primary effusion lymphoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02119468 Background | Jun 2014 → May 2016 | plasma cell myeloma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02185820 Background | Jun 2014 → Jul 2015 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT01997840 Background | Mar 2014 → Feb 2024 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT01665794 Background | Aug 2012 → Nov 2025 | plasma cell myeloma | University of Chicago | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT06948084 Comparator | Aug 2026 → Feb 2028 expected | plasma cell myeloma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07096778 Background | Jan 2026 → Dec 2029 expected | plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06594432 Background | Oct 2024 → Dec 2026 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05050305 Background | Mar 2024 → Dec 2025 | plasma cell myeloma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT05669989 Background | Apr 2023 → Nov 2026 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04700176 Background | May 2022 → Nov 2023 | plasma cell myeloma | Hackensack Meridian Health | Terminated | No outcome recorded |
| Phase 2 | NCT05298683 Background | May 2022 → Nov 2025 | impaired renal function disease, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Unknown | No outcome recorded |
| Phase 2 | NCT05066607 Background | Feb 2022 → Mar 2026 | AL amyloidosis | Intergroupe Francophone du Myelome | Unknown | No outcome recorded |
| Phase 2 | NCT04790474 Background | Mar 2021 → Mar 2026 overdue | plasma cell myeloma | Tel-Aviv Sourasky Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03841565 Background | Aug 2020 → Feb 2022 | plasma cell myeloma | Academic and Community Cancer Research United | Withdrawn | No outcome recorded |
| Phase 2 | NCT04176718 Background | May 2020 → May 2027 expected | plasma cell myeloma | Andrew Yee, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03567616 Background | Oct 2018 → Jun 2020 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT03170882 Comparator | Aug 2017 → Aug 2020 | refractory plasma cell neoplasm | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02719613 Background | Jul 2016 → Feb 2026 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02654132 Background | Mar 2016 → Jan 2018 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02294357 Background | Dec 2014 → Sep 2020 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT01053949 Comparator | Oct 2009 → Apr 2014 | plasma cell myeloma | University Hospital, Lille | Completed | No outcome recorded |
| Phase 329 trials | ||||||
| Phase 3 | NCT07555938 Background | Jun 2026 → Oct 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07623798 Comparator | Jun 2026 → May 2029 expected | refractory plasma cell neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07569757 Comparator | Jun 2026 → Dec 2028 expected | plasma cell myeloma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07452198 Comparator | Mar 2026 → Mar 2029 expected | plasma cell myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07391657 Comparator | Feb 2026 → Jun 2028 expected | refractory plasma cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07579234 Comparator | Jan 2026 → Jan 2029 expected | refractory plasma cell neoplasm | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 3 | NCT06615479 Background | Mar 2025 → Dec 2027 expected | refractory plasma cell neoplasm | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06742138 Background | Jan 2025 → Dec 2027 expected | plasma cell myeloma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06413498 Comparator | Aug 2024 → Jul 2028 expected | plasma cell myeloma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06508983 Background | Jun 2024 → Mar 2027 expected | refractory plasma cell neoplasm | Hangzhou Sumgen Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06232707 Comparator | May 2024 → Nov 2025 | plasma cell myeloma | Celgene Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT06464991 Comparator | Mar 2024 → Aug 2027 expected | plasma cell myeloma | Nanjing IASO Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06152575 Comparator | Feb 2024 → Aug 2026 overdue | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05730036 Comparator | Sep 2023 → Apr 2033 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05675319 Comparator | Mar 2023 → Mar 2025 | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded |
| Phase 3 | NCT05438043 Background | Dec 2022 → Jan 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05405166 Background | Jun 2022 → Nov 2024 overdue | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05028348 Background | Apr 2022 → Mar 2026 overdue | plasma cell myeloma | European Myeloma Network B.V. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06956170 Background | Feb 2022 → May 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05020236 Comparator | Oct 2021 → Apr 2026 overdue | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT04484623 Background | Oct 2020 → Jan 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04162210 Comparator | Apr 2020 → Sep 2022 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03539744 Comparator | Oct 2018 → Aug 2026 overdue | plasma cell myeloma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03143049 Background | Sep 2017 → Jun 2018 | — | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 3 | NCT03180736 Background | Jun 2017 → Jul 2020 | plasma cell myeloma | Stichting European Myeloma Network | Completed | No outcome recorded |
| Phase 3 | NCT03151811 Comparator | Jun 2017 → Feb 2021 | plasma cell myeloma | Oncopeptides AB | Terminated | No outcome recorded |
| Phase 3 | NCT02990338 Background | Dec 2016 → Nov 2018 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02726581 Background | Aug 2016 → Mar 2022 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02576977 Background | Oct 2015 → Jul 2018 | plasma cell myeloma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 295 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pomalidomide | “Patients will receive APG-2575 at target dose once daily for 28 days plus pomalidomide (4 mg ) on Days 1 through 21 and dexamethasone (40 mg for patients ≤ 75 years old or 20...” NCT04942067 ↗282“Patient eligible to enter the study will receive 9 to 12 cycles (according to response) of intravenous Isatuximab (10 mg/kg) and oral Pomalidomide 4 mg from day 1 to day 21 and...” NCT05066607 ↗ “The proposed study is an open-label, single-arm, Phase-Ib/II trial to assess the efficacy of oral drug combination ruxolitinib and pomalidomide in primary and secondary MF patients.” NCT01644110 ↗ “the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.” NCT06594432 ↗ “Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle” NCT05828459 ↗ “Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients” NCT02188368 ↗ “Given that pomalidomide is an FDA approved drug for patients with relapsed or progressive myeloma” NCT01889420 ↗ “Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle” NCT07072208 ↗ “Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle.” NCT03215524 ↗ “Pomalidomide: 4mg/day oral route on 21 days per cycle” NCT02244125 ↗ “DTRM-555 (DTRMWXHS-12, everolimus and pomalidomide)” NCT04305444 ↗ “Pomalidomide is a new immunomodulatory drug” NCT03143049 ↗ “DTRMWXHS-12 and everolimus and pomalidomide” NCT02900716 ↗ “Golidocitinib combined with Pomalidomide” NCT06855823 ↗ “Pomalidomide 4mg orally daily, d1-21;” NCT06158412 ↗ “Pomalidomide: 4 mg/d d1-d21, orally” NCT06246162 ↗ “Pomalidomide (POM)” NCT01575925 ↗ “Drug: Pomalidomide” NCT03763370 ↗ “Pomalidomide” NCT07312188 ↗ |
| Known as | Actimid | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | CC-4047 | “The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are...” NCT00717522 ↗14“A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV” NCT01495598 ↗ “A Phase 1, Double-blind, Four Period Crossover Study to Investigate the Effects of Pomalidomide (CC 4047) on the QT Interval in Healthy Male Subjects” NCT01986894 ↗ “Pomalidomide (CC-4047) is a drug given by mouth, which can change or regulate the functioning of the immune system.” NCT01570387 ↗ “Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance” NCT01745588 ↗ “Pomalidomide (CC-4047) in Combination With Low-Dose Dexamethasone” NCT02045017 ↗ “pomalidomide (CC-4047)” NCT02659930 ↗ “Pomalidomide (CC-4047)” NCT01559129 ↗ “pomalidomide (CC-4047” NCT01135199 ↗ |
| Known as | IMID 3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Imnovid | “Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle” NCT05651932 ↗1“Imnovid (pomalidomide)” NCT02046915 ↗ |
| Known as | Imnovid (previously pomalidomide celgene) | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | POM | “This phase 1b study (NCT02431208) evaluated the safety and efficacy of the anti-programmed death-ligand 1 monoclonal antibody atezolizumab (Atezo) alone or in combination with...” PMID 37559718 ↗ Jul 20235“We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA with pomalidomide (POM) and dexamethasone (DEX) in lenalidomide (LEN)/PI-refractory MM.” PMID 34559902 ↗ Oct 2021 “We conducted a prospective phase 2 study investigating the safety and efficacy of pomalidomide (POM) in children and young adults with recurrent and progressive primary brain tumors.” PMID 34168987 ↗ Jun 2021 “This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A)” NCT01946477 ↗ “Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd)” NCT03651128 ↗ “pomalidomide (POM) plus low-dose dexamethasone (POM + LoDEX)” PMID 26149712 ↗ Jun 2015 |
| Known as | Pomalidomida | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide (POM) | “Pomalidomide (POM)” NCT01575925 ↗ |
| Known as | Pomalidomide (Pomalyst, Imnovid) | “Pomalidomide (Pomalyst, Imnovid)” NCT05651932 ↗ |
| Known as | Pomalidomide accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide krka | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide viatris | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide zentiva | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide( Anyue, Chia Tai TIANQING, China) | “Pomalidomide( Anyue®, Chia Tai TIANQING, China)” NCT04762745 ↗ |
| Known as | Pomalyst | “The study drug, pomalidomide (POMALYST®), has been approved by the United States Food and Drug Administration (FDA) to treat patients with multiple myeloma (MM).” NCT01835561 ↗2“Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle” NCT05651932 ↗ “pomalidomide (also known as Pomalyst)” NCT01745588 ↗ |
| Action | Inhibit | “in vitro suppression of TNF-α production” NCT00770757 ↗ |
| Modality | Other / unclassified | “Pomalidomide is a distinct oral IMiD(®) immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects.” PMID 26160879 ↗ Jul 2015 |
| Route | Oral | “Participants received 2 mg oral pomalidomide daily” NCT00463385 ↗ |
| Target | TNF | “in vitro suppression of TNF-α production” NCT00770757 ↗ |